Previous 10 | Next 10 |
Aging population, lifestyle changes and pandemics have created a huge demand for patient-focused healthcare. Biotech stocks like Seagen (SGEN), Genmab A/S (GMAB), Amedisys (AMED), and Masimo (MASI) could dominate the industry based on their disruptive technology, unique offerings and tremendo...
NantKwest announces initiation of second generation COVID-19 vaccine candidate. Protagonist Therapeutics receives orphan drug status for PTG-300. Genmab reports positive data from Phase 2 CASSIOPEIA study. For further details see: NantKwest COVID-19 Candidate, And Other ...
Genmab A/S (GMAB) announces positive results from the second part of a Phase 3 clinical trial, CASSIOPEIA, evaluating daratumumab as maintenance treatment versus no treatment in newly diagnosed multiple myeloma ((MM)) patients who are eligible for autologous stem cell transplantation.Part 2, ...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
Genmab has continued to make great progress since my initial coverage a year ago. The company's portfolio of current and future therapeutics in association with world-class partners bodes well for continued breakthroughs in the fight against cancer. However, one issue of concern m...
Amgen (AMGN), Genmab A/S (GMAB), Seattle Genetics (SGEN), and Alexion Pharmaceuticals (ALXN) are leading biotech companies engaged in developing cancer drugs. As the number of cancer patients rises with each passing day, these stocks should continue to move higher. Biotech stocks are amon...
Agenus's balstilimab and zalifrelimab nears FDA submission for cervical cancer. Seattle Genetics presented tisotumab vedotin cervical cancer data at ESMO. They may compete in the marketplace despite differing mechanisms of action. For further details see: Agenus Vs. Seat...
Moderna (MRNA) is one of the leading biotech manufacturers in the race to develop a coronavirus vaccine. The stock seems overvalued by traditional measures, but the company’s unique approach to developing the vaccine could move the stock in either direction. Moderna, Inc. (...
InSysBio collaborates with Genmab ([[GMAB]] -8.8%) for GEN1042, a bispecific agonistic antibody for solid tumors.The key aim of this collaboration is to develop a quantitative system pharmacology ((QSP)) model that allows exploration of the relationships between dose, schedule, and tumor...
AC Immune SA (ACIU) -43% as semorinemab flunks Alzheimer's study.Wave Life Sciences (WVE) -31% after pricing equity offering.Aurora Cannabis (ACB) -17% on soft revenue outlook.NanoVibronix (NAOV) -17% after increasing the size of the previous publi...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Innovative Eyewear Inc. (LUCY) rose 78.0% to $0.58749 on volume of 130,454,575 shares Ocean Power Technologies Inc. (OPTT) rose 29.6% to $0.2073 on volume of 51,927,154 shares Cosmos Health Inc. (COSM) rose 64.9% to $1.12 on volume of...
Company Announcement Positive CHMP opinion based on results from the Phase 1/2 EPCORE ® NHL-1 study FL is the second most common type of NHL and accounts for approximately 20-30 percent of all global cases If approved, epcoritamab (TEPKINLY ® ...
2024-06-27 09:00:08 ET Kaveri Pohlman from BTIG issued a price target of $47.00 for GMAB on 2024-06-27 07:34:00. The adjusted price target was set to $47.00. At the time of the announcement, GMAB was trading at $25.67. The overall price target consensus is at $41.80 with...